Nanomix (Nanomix) ROCE % : 0.00% (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Nanomix ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nanomix's annualized ROCE % for the quarter that ended in Dec. 2022 was 0.00%.

Nanomix ROCE % Historical Data

The historical data trend for Nanomix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanomix ROCE % Chart

Nanomix Annual Data

Trend

Dec20

Dec21

Dec22

ROCE %

Nanomix Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
ROCE %	Get a 7-Day Free Trial						-	-	-	-	-

Nanomix ROCE % Calculation

Nanomix's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-8.225	/	( ( (0.906 - 3.325)	+	(0.982 - 4.05) )	/ 2 )
	=	-8.225	/	( (-2.419	+	-3.068)	/ 2 )
	=	-8.225	/	-2.7435
	=	299.80 %

Nanomix's ROCE % of for the quarter that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	-7.444	/	( ( (1.013 - 3.897)	+	(0.982 - 4.05) )	/ 2 )
	=	-7.444	/	( ( -2.884	+	-3.068 )	/ 2 )
	=	-7.444	/	-2.976
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

Nanomix (OTCPK:NNMX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nanomix ROCE % Related Terms

Thank you for viewing the detailed overview of Nanomix's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanomix (Nanomix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2121 Williams Street, San Leandro, CA, USA, 94577

Website

https://www.nanomixdx.com

Nanomix Corp develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. Its products include The Nanomix eLab System, COVID-19 Rapid Antigen Panel, and Critical Infection and Host Response. The company's products improve healthcare delivery by bringing the diagnostic information to the point of initial patient interaction, whether in the hospital or settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more.

Executives

Chris Hetterly	officer: Chief Financial Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Garrett Gruener	director, 10 percent owner	ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Thomas Schlumpberger	director, officer: CEO	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Vidur Sahney	officer: Chief Operating Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
John Hardesky	officer: Chief Commercial Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
David Ludvigson	director, officer: CEO and President	BLACK PEARL INC, 400 SECOND ST STE 450, SAN FRANCISCO CA 94107
Gregory T Schiffman	director	1030 NW JOHNSON ST, UNIT 608, PORTLAND OR 97209
Loraine Upham	officer: Chief Operating Officer	C/O BOSTON THERAPEUTUCS INC., 354 MERRIMACK ST, #4, LAWRENCE MA 01843
Carl W Rausch	director, officer: CEO
Alan M Hoberman	director	6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Cheng Conroy Chi-heng	director	ADVANCE PHARMACEUTICAL CO LTD, 3/F, GMP CENTRE, 12 DAI FU STREET, TAI PO K3 280
Anthony Don Squeglia	officer: Chief Financial Officer	PRO-PHARMACEUTICALS, INC., 7 WELLS AVENUE, SUITE 34, NEWTON MA 02459
Neill Sydney Colin	director	C/O AXONYX INC, 500 SEVENTH AVE 1OTH FLOOR, NEW YORK NY 10018
Jonathan B Rome	officer: Chief Operating Officer (3)	178 WEST SADDLE RIVER ROAD, SADDLE RIVER NJ 07458
Rom E Eliaz	director	33 KACHAL STREET, LEHAVIM L3 85338